Journal of Psychoactive Drugs
June 1, 2017
Álvaro José Palma-Conesa, Mireia Ventura, Liliana Galindo et al.
65 citations
New psychoactive tryptamines, which mimic the effects of regulated hallucinogens, pose a potential public health risk. Analysis of 25,296 samples submitted to a harm-reduction organization from 2006 to 2015 identified 436 tryptamines, of which 232 (53.21%) were not regulated. The most common unregulated tryptamine was 4-AcO-DMT, for which no human studies exist. Unregulated tryptamines were more likely to contain a single unadulterated substance. The number of tryptamine samples increased over time, and there were significant differences between client expectations and actual analysis results for regulated versus unregulated groups. Further research is needed to address health risks.
Microchemical Journal
February 28, 2023
María Mata-Pesquera, David Fabregat‐safont, Cristina Gil et al.
10 citations
A recently detected synthetic cathinone, N-cyclohexyl butylone, was characterized using gas chromatography–mass spectrometry, liquid chromatography–high-resolution mass spectrometry, nuclear magnetic resonance, and Fourier-transform infrared spectroscopy. The compound's elemental composition and molecular structure were determined from accurate-mass ions and two-dimensional NMR experiments. In silico predictions suggest that N-cyclohexyl butylone likely produces stimulant effects similar to MDMA. This work provides a complete analytical profile for a new psychoactive substance that has appeared in European drug markets.
European Psychiatry
March 1, 2016
Á. Palma Conesa, L. Galindo Guarín, M. Grifell Guàrdia et al.
From 2009 to 2014, a Spanish harm reduction service analyzed over 17,000 drug samples and found the new psychoactive tryptamines 4-HO-DiPT and 4-AcO-DiPT in 16 samples each, and DiPT in only 4. Nine samples contained both 4-HO-DiPT and 4-AcO-DiPT. Deliveries of 4-HO-DiPT increased over the study period (4 samples in 2014), while those of 4-AcO-DiPT and DiPT decreased (1 sample each in 2014). This trend suggests a progressive replacement of 4-AcO-DiPT and DiPT by 4-HO-DiPT for recreational use. Clinical concern arises from the growing use and lack of scientific evidence on humans, with effects predicted only from users' subjective experiences.